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spirin Resistance
ransient Laboratory Finding
r Important Clinical Entity?*
li I. Lev, MD
etah-Tikva and Tel Aviv, Israel
or the past decade, extensive research has been devoted to
tudy and characterize variability in the biologic response to
spirin. More than 500 publications have focused on the
opic of aspirin “resistance”—low response to the antiplate-
et effects of aspirin. Despite the numerous studies, substan-
ial controversy still exists regarding the essence of this
henomenon: its definition, prevalence, potential mecha-
isms, and clinical implications.
See page 667
Aspirin acetylates a serine residue at position 529 on the
yclooxygenase (COX)-1 enzyme in platelets, thus blocking
ransformation of arachidonic acid (AA) to the potent
latelet agonist thromboxane (TX) A2 (1). Inhibition of TX
ynthesis and TX-dependent platelet aggregation is pre-
umed to be the main mechanism for aspirin’s antithrom-
otic effect (1). Response to aspirin has been evaluated by
everal laboratory methods (2–4). The most commonly used
s light transmission aggregation in response to AA, aden-
sine diphosphate (ADP), or collagen (among them, AA
est reflects COX-1–dependent platelet activation). A more
pecific method to detect COX-1 function, and therefore
spirin effect, is measurement of TXA2 metabolites, such as
erum TXB2 and urinary 11-dehydro-TXB2. Finally, several
oint-of-care assays have been developed to assess response
o aspirin, such as VerifyNow Aspirin (Accumetrics Inc.,
an Diego, California) (2–4). The prevalence of laboratory-
efined aspirin resistance (also termed low or inadequate
esponse to aspirin) is heavily dependent on the assay used,
ut-off value chosen, and population tested. A wide range of
revalence rates have therefore been reported, ranging from
1% to 60% of the subjects tested (2–4).
The clinical significance of aspirin resistance has been
valuated mainly in small studies that have used a variety of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiology Department, Rabin Medical Center, Petah-Tikva, Israel; and
he Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.ethodologies, but evidence of an association with in-
reased risk of cardiovascular events is gradually accruing.
ost of the clinical data have been attained using functional
ssays (e.g., platelet aggregation) or urinary 11-dehydro-
XB2. High levels of urinary 11-dehydro-TXB2, reflecting
ncomplete inhibition of TX formation by aspirin, were
ssociated with an almost 2-fold increased risk of cardio-
ascular death, myocardial infarction (MI), or stroke in
atients from the HOPE (Heart Outcomes Prevention
valuation) and CHARISMA (Clopidogrel for High
therothrombotic Risk and Ischemic Stabilization, Man-
gement and Avoidance) trials (5,6). In patients with stable
oronary artery disease and patients undergoing nonurgent
ercutaneous coronary intervention, aspirin resistance de-
ned by platelet aggregation (in response to AA and ADP)
r the VerifyNow Aspirin assay, was associated with an
ncreased risk of adverse events including death, MI, or
troke (7), or post-procedural myonecrosis (8,9). Finally, 2
ecent meta-analyses encompassing 15 to 20 studies (albeit
ighly heterogeneous) and totaling almost 3,000 patients
howed that aspirin resistance was associated with an odds ratio
f almost 4 for development of cardiovascular events (10,11).
Despite the emerging evidence indicating an association
ith clinical outcomes, many fundamental questions regard-
ng aspirin resistance are still unanswered. Of particular
nterest, how stable is this phenomenon temporally, and
ow reproducible are the results of the various assays? In this
espect, the study by Santilli et al. (12) in this issue of the
ournal adds important novel information. This comprehen-
ive and thorough study evaluated the effect of low-dose
spirin using a variety of functional and biochemical assays
n 48 healthy volunteers randomized to receive aspirin for
arious intervals (1 to 8 weeks). Up to 8 repeated measures
f platelet function were performed in each subject, includ-
ng analysis of recovery of platelet function following aspirin
ithdrawal. The study has 3 important findings:
. Using any functional assay, subjects found to be resistant
to aspirin at a specific time point were found to be
responsive on previous or subsequent measurements.
Thus, in healthy subjects, laboratory-determined aspirin
resistance, assessed at a single time point, does not appear
to be a stable phenomenon over time!
. Aspirin induced a uniform and steady suppression of
serum TXB2 levels by 99% with very little interindi-
vidual or intraindividual variation (1%). Platelet inhi-
bition tested using AA-induced aggregation, the Veri-
fyNow Aspirin assay, and urinary 11-dehydro-TXB2
levels remained relatively stable, averaging 80%, 35%,
and 65%, respectively, with an intrasubject variation of
approximately 20% over the 8-week period. Similar TX
inhibition was observed in a larger study by Faraday et
al. (13) (n  1,880 subjects without repeated measures),
in which aspirin uniformly inhibited ex vivo production
of TXB2 (by99%), with less pronounced inhibition of
urinary 11-dehydro-TXB2. Suppression of ADP- and
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February 24, 2009:678–80 Aspirin Resistancecollagen-induced aggregation was highly variable. Inter-
estingly, there was no linear correlation between inhi-
bition of serum TXB2 and the other assays (including
urinary 11-dehydro-TXB2). However, AA-induced ag-
gregation, VerifyNow Aspirin, and urinary 11-dehydro-
TXB2 levels correlated well with each other (correlation
coefficients approximately 0.7), in contrast to the poor
correlation found in a previous study that did not
include repeated measurements (14).
. Recovery of platelet function, assessed by the functional
assays, reached approximately 70% of the baseline level
at day 3 post-aspirin. This unexpectedly short period of
time may have important implications for recommen-
dations concerning aspirin withdrawal prior to surgical
procedures.
The main limitation of the study by Santilli et al. (12) is
hat it was conducted in young (mean age 26 years), healthy
ndividuals. Therefore, the application of these results to a
opulation of much older patients with cardiovascular dis-
ase, comorbidities, and numerous adjunctive medications is
uestionable and should be further examined. Nevertheless,
he interesting findings mentioned previously raise 2
roader questions:
. Can an apparently transient unstable state, assessed
using a single measurement of aspirin response, be
associated with and predict potential clinical outcomes?
. What is the reason for the nonlinear relation between
serum TXB2 levels and the functional assays, and which
measure better reflects response to aspirin?
Several mechanisms for aspirin resistance have been
roposed, among them poor patient compliance, inade-
uate aspirin dose, concomitant use of nonsteroidal anti-
nflammatory drugs, rare genetic polymorphisms of COX-1,
nd especially relevant for the current discussion, increased
latelet turnover rate and basal platelet hyper-reactivity
3,4). Both of these factors can be temporary and variable.
aseline platelet reactivity is an important determinant of
ost-aspirin (residual) platelet function (15,16). Increased
latelet reactivity, via COX-1 and non–COX-1 pathways,
an often be observed in acute conditions, such as acute
oronary syndromes. Indeed, patients with acute MI display
latelet hyper-reactivity and have an increased prevalence of
spirin resistance (17), which has been associated with
dverse cardiac events (18). Enhanced platelet turnover,
hich is intertwined with platelet hyper-reactivity, causes
elease of young platelets still able to form TX (despite
spirin treatment) via uninhibited COX-1 and possibly
hrough up-regulated COX-2. In both healthy subjects and
atients with coronary artery disease, increased platelet
urnover, as reflected by the level of reticulated platelets, has
een associated with diminished response to aspirin (19,20).
t is conceivable that in transient conditions associated with
ncreased platelet turnover and reactivity, such as acute
oronary syndromes or coronary artery bypass grafting, lowesponse to aspirin may be associated with an increased risk
or thrombotic complications. In such scenarios, aspirin
esistance does not necessarily have to be an “all or none”
onstant phenotype to have clinical significance.
Regarding the second question, serum TXB2 is the most
irect and specific laboratory measure for TX generated by
latelet COX-1 and therefore for COX-1 inhibition by
spirin. The nonlinear relationship between serum TXB2
evels and other assays, also noted in previous studies (4),
ay reflect other sources of TX or platelet activation by
ther pathways. For instance, urinary 11-dehydro-TXB2
evels may be affected by extraplatelet sources of TX, such as
ascular or renal sources, or by COX-2–mediated TX
eneration (4). AA-induced aggregation may be affected by
elease of secondary agonists. Aggregation in response to
DP and collagen involves COX-1–independent pathways
nd possibly secondary TX-related pathways. In aspirin-
reated patients, activation along these COX-1–independent
athways may contribute to residual platelet reactivity (16,21),
hich in turn has been associated with adverse clinical
utcome (21). The question of which assay best reflects
esponse to aspirin depends on the purpose of the test. If the
im is to predict risk of cardiovascular events in patients
reated with aspirin, measurement of residual platelet reac-
ivity (induced by AA and possibly other pathways), and
rinary 11-dehydro-TXB2 may be advantageous, as evi-
enced by the clinical data generated so far (5–11).
The results presented in the study by Santilli et al. (12)
nswer several questions but raise others. The findings
egarding the transient nature of aspirin resistance should be
urther explored in patients with cardiovascular disease,
ncluding settings of acute coronary syndromes, percutane-
us coronary intervention, and others. More importantly, a
arge-scale, prospective study using an acceptable common
efinition of aspirin resistance, preferably based on several
ssays, should be performed to clearly establish the long-
erm clinical significance of this phenomenon and accord-
ngly the need to modify and tailor antiplatelet treatment in
esistant patients.
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